» Articles » PMID: 37455756

The Recovery Strategies to Support Cervical Cancer Elimination in Lower-and Middle-income Countries (LMICs) Following COVID-19 Disruptions

Overview
Journal Prev Med Rep
Date 2023 Jul 17
PMID 37455756
Authors
Affiliations
Soon will be listed here.
Abstract

The COVID-19 pandemic has exacerbated the existing challenges to achieving the WHO target of eliminating cervical cancer as a public health problem by working towards the target of fewer than four cases per 100 000 women. We reviewed the literature to identify potential recovery strategies to support cervical cancer prevention programs in lower-and middle-income countries (LMICs) following COVID-19 disruptions and the extent to which strategies have been implemented. Utilising the WHO health systems framework, we mapped these recovery strategies against the six building blocks to examine their reach across the health system. Most recovery strategies were focused on service delivery, while leadership and governance played a pivotal role in the continuity of cervical cancer prevention programs during the pandemic. Leadership and governance were the drivers for outcomes in the building blocks of health information systems, financing and critical support in operationalising service delivery strategies. In the aftermath of the COVID-19 pandemic with strained health resources and economies, stakeholders would significantly influence the coverage and sustainability of cervical cancer prevention programs. The support from multisectoral stakeholders would accelerate the recovery of cervical cancer prevention programs. To achieve the WHO target by 2030, we call for future studies to understand the barriers and facilitators from the perspectives of stakeholders in order to support the decision-making processes and information required to implement recovery strategies in LMICs.

Citing Articles

From barriers to opportunities from COVID-19 pandemic: Stakeholder perspectives on cervical cancer screening programs in LMICs of the Asia-Pacific region.

Lee J, Ismail-Pratt I, Machalek D, Kumarasamy S, Garland S PLOS Glob Public Health. 2024; 4(10):e0003768.

PMID: 39365795 PMC: 11451976. DOI: 10.1371/journal.pgph.0003768.


Human Papillomavirus Vaccination Acceleration and Introduction in Sub-Saharan Africa: A Multi-Country Cohort Analysis.

Adeyanju G, Essoh T, Sidibe A, Kyesi F, Aina M Vaccines (Basel). 2024; 12(5).

PMID: 38793741 PMC: 11125825. DOI: 10.3390/vaccines12050489.


A Comprehensive Integration of Data Regarding the Correlation of TNF-α rs1800629 Polymorphism with Susceptibility to Cervical Cancer.

Marzbanrad Z, Karimi-Zarchi M, Noei-Teymoordash S, Motamedinasab M, Azizi S, Noori-Ardebili S Asian Pac J Cancer Prev. 2024; 25(4):1155-1167.

PMID: 38679974 PMC: 11162705. DOI: 10.31557/APJCP.2024.25.4.1155.

References
1.
Roozen G, Roukens A, Roestenberg M . COVID-19 vaccine dose sparing: strategies to improve vaccine equity and pandemic preparedness. Lancet Glob Health. 2022; 10(4):e570-e573. PMC: 8923677. DOI: 10.1016/S2214-109X(22)00075-4. View

2.
Woo Y, Gravitt P, Khor S, Ng C, Saville M . Accelerating action on cervical screening in lower- and middle-income countries (LMICs) post COVID-19 era. Prev Med. 2021; 144:106294. PMC: 7931730. DOI: 10.1016/j.ypmed.2020.106294. View

3.
de Sanjose S, Holme F . What is needed now for successful scale-up of screening?. Papillomavirus Res. 2019; 7:173-175. PMC: 6477512. DOI: 10.1016/j.pvr.2019.04.011. View

4.
Taghavi K, Moono M, Asangbeh S, Gillett G, Pascoe M, Manasyan A . Strengthening global commitment to eliminating cervical cancer: What lessons from the past can we apply to the future?. J Glob Health. 2020; 10(2):020385. PMC: 7648905. DOI: 10.7189/jogh.10.020385. View

5.
Budukh A, Dikshit R, Chaturvedi P . Outcome of the randomized control screening trials on oral, cervix and breast cancer from India and way forward in COVID-19 pandemic situation. Int J Cancer. 2021; 149(8):1619-1620. PMC: 8427005. DOI: 10.1002/ijc.33712. View